4.1 Article

The Swedish motor neuron disease quality registry

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/21678421.2018.1497065

关键词

Amyotrophic lateral sclerosis; motor neuron disease; national registry; prospective cohort; epidemiology

向作者/读者索取更多资源

Objective: We set up the Swedish Motor Neuron Disease (MND) Quality Registry to assure early diagnosis and high-quality health care for all MND patients (mainly amyotrophic lateral sclerosis, ALS), and to create a research base by prospectively following the entire MND population in Sweden. Methods: Since 2015, the MND Quality Registry continuously collects information about a wide range of clinical measures, biological samples, and quality of life outcomes from all MND patients recruited at the time of MND diagnosis in Sweden and followed at each clinic visit approximately every 12 weeks. The Registry includes an Internet based patient own reporting portal that involves patients in the registration of their current symptoms and health status. Results: As of 20th January 2017, the MND Quality Registry included 99% of the MND patients of the Stockholm area (N = 194), consisting mostly of ALS patients (N = 153, 78.9%), followed by patients labeled as MND due to a neurophysiology finding but not fulfilling the criteria for ALS (N = 20, 10.3%), primary lateral sclerosis (N = 13, 6.7%), and progressive spinal muscular atrophy patients (N = 8, 4.1%). A higher proportion of these patients were women (N = 100, 52%), and women and men had a similar age at symptoms onset (59 years). Conclusions: Main strengths of the MND Quality Registry are its clinical, quantitative, qualitative, and prospective nature, providing the researchers potential means of identifying appropriate candidates for clinical trials and other research projects, as well as assuring to the patients an effective and adequate time spent on-site with the healthcare professionals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study

Elisa Longinetti, Olafur Sveinsson, Rayomand Press, Weimin Ye, Caroline Ingre, Fredrik Piehl, Fang Fang

Summary: The study found that the high concurrence of ALS and MS/MG/IP/DMPM diagnoses is mainly due to diagnostic uncertainty, with only a minority of patients truly having a co-occurrence of ALS and autoimmune diseases. Some patients were diagnosed with MG shortly after the onset of ALS, suggesting that neurodegeneration may trigger autoimmunity.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2022)

Article Clinical Neurology

Cardiac troponin T is elevated and increases longitudinally in ALS patients

Ulf Klappe, Sanharib Chamoun, Qing Shen, Anja Finn, Bjorn Evertsson, Henrik Zetterberg, Kaj Blennow, Rayomand Press, Kristin Samuelsson, Anna Manberg, Fang Fang, Caroline Ingre

Summary: NfL is a stronger diagnostic and prognostic biomarker than hs-cTnT for ALS, however, hs-cTnT may serve as a marker for disease progression as it increases over time. Further investigation is needed to understand the underlying reasons for this increase.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2022)

Article Public, Environmental & Occupational Health

Comparison of two different frailty scales in the longitudinal Swedish Adoption/Twin Study of Aging (SATSA)

Alexandra M. Wennberg, Weiyao Yin, Fang Fang, Nancy L. Pedersen, Sara Hagg, Juulia Jylhava, Karin Modig

Summary: This study evaluated the utility of a code-based frailty score in registry data and found that it may not capture the full spectrum of frailty among community-dwelling individuals, particularly at younger ages.

SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2023)

Article Immunology

The FOXP3 full-length isoform controls the lineage-stability of CD4+FOXP3+ regulatory T cells

Christina Seitz, Anne-Laure Joly, Fang Fang, Katie Frith, Paul Gray, John Andersson

Summary: The transcription factor FOXP3 is crucial for the development and function of CD4(+)FOXP3(+) regulatory T (Treg) cells. Alterations in the expression of FOXP3 isoforms are associated with inflammatory disease progression. This study investigates the effects of a specific FOXP3 mutation on Treg cell subsets. The findings suggest that the full-length FOXP3 isoform is important for maintaining Treg cell lineage stability but not essential for Treg cell activation.

CLINICAL IMMUNOLOGY (2022)

Article Clinical Neurology

The path to diagnosis in ALS: delay, referrals, alternate diagnoses, and clinical progression

Stefan Sennfalt, Ulf Klappe, Sebastian Thams, Kristin Samuelsson, Rayomand Press, Fang Fang, Caroline Ingre

Summary: This study aimed to provide a detailed description of the path to a correct diagnosis of amyotrophic lateral sclerosis (ALS), including delays, referrals, alternate diagnoses, and clinical progression. The study found significant variations in the diagnostic pathway based on the clinical phenotype, with substantial delays and clinical progression in all groups.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Dying from ALS in Sweden: clinical status, setting, and symptoms

Stefan Sennfalt, Ulf Klappe, Sebastian Thams, Kristin Samuelsson, Rayomand Press, Fang Fang, Caroline Ingre

Summary: This retrospective cohort study provides a comprehensive account of death in Swedish patients with ALS, including the clinical status preceding death, the death setting, and symptoms. The majority of patients died in their own homes or at a palliative unit in the presence of next of kin, and most symptoms were adequately managed.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Review Clinical Neurology

UNC13A in amyotrophic lateral sclerosis: from genetic association to therapeutic target

Sean W. Willemse, Peter Harley, Ruben P. A. van Eijk, Koen C. Demaegd, Pavol Zelina, R. Jeroen Pasterkamp, Philip van Damme, Caroline Ingre, Wouter van Rheenen, Jan H. Veldink, Matthew C. Kiernan, Ammar Al-Chalabi, Leonard H. van den Berg, Pietro Fratta, Michael A. van Es

Summary: Amyotrophic lateral sclerosis (ALS) is a deadly neurodegenerative disease with limited treatment options. A specific gene polymorphism in the UNC13A gene has been found to increase the risk of ALS and frontotemporal dementia (FTD), and can modify the disease phenotype in ALS patients. UNC13A is involved in maintaining synaptic active zones and its depletion leads to impaired neurotransmission. Recent discoveries have identified UNC13A as a potential therapeutic target, with ongoing trials using lithium carbonate and considering antisense oligonucleotides. Knowledge of UNC13A's distinct phenotype is important for future clinical trials.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Diagnostic delay in amyotrophic lateral sclerosis

Kelly G. Gwathmey, Philippe Corcia, Chris J. McDermott, Angela Genge, Stefan Sennfalt, Mamede de Carvalho, Caroline Ingre

Summary: ALS is a fatal neurodegenerative disease with a long delay in diagnosis. This delay is influenced by lack of recognition and misdiagnosis by general practitioners, as well as patient factors such as illness behavior and site of symptom onset.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Jeremy M. Shefner, Ammar Al-Chalabi, Jinsy A. Andrews, Adriano Chio, Mamede De Carvalho, Bettina M. Cockroft, Philippe Corcia, Philippe Couratier, Merit E. Cudkowicz, Angela Genge, Orla Hardiman, Terry Heiman-Patterson, Robert D. Henderson, Caroline Ingre, Carlayne E. Jackson, Wendy Johnston, Noah Lechtzin, Albert Ludolph, Nicholas J. Maragakis, Timothy M. Miller, Jesus S. Mora Pardina, Susanne Petri, Zachary Simmons, Leonard H. Van Den Berg, Lorne Zinman, Stuart Kupfer, Fady I. Malik, Lisa Meng, Tyrell J. Simkins, Jenny Wei, Andrew A. Wolff, Stacy A. Rudnicki

Summary: The objective of this study is to determine the target population and optimize the study design for the phase 3 clinical trial of reldesemtiv in ALS participants. The phase 2 study, FORTITUDE-ALS, showed that reldesemtiv had a significant effect on participants with intermediate and fast disease progression, leading to the implementation of specific eligibility criteria and design features in the phase 3 trial, COURAGE-ALS, to increase sensitivity in detecting treatment effects and reduce burden on participants and study sites.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

PRECISION ALS-an integrated pan European patient data platform for ALS

Robert McFarlane, Miriam Galvin, Mark Heverin, Eanna Mac Domhnaill, Deirdre Murray, Dara Meldrum, Peter Bede, Anthony Bolger, Lucy Hederman, Sinead Impey, Gaye Stephens, Ciara O'Meara, Vincent Wade, Ammar Al Chalabi, Adriano Chio, Phillippe Corcia, Philip van Damme, Caroline Ingre, Christopher McDermott, Monica Povedanos, Leonard Van den Berg, Orla Hardiman

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

FDG-PET shows weak correlation between focal motor weakness and brain metabolic alterations in ALS

Stefan Sennfalt, Marco Pagani, Fang Fang, Irina Savitcheva, Ulrika Estenberg, Caroline Ingre

Summary: This study aimed to investigate the correlation between focal motor weakness and metabolic alterations in specific areas of the brain in ALS patients using FDG-PET, including longitudinal imaging. The results showed a general pattern of brain metabolic alterations consistent with previous findings in ALS. However, there was no clear correlation between focal motor weakness and specific metabolic alterations. Further research, particularly with larger sample sizes and longitudinal imaging, is needed.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

Elisa Longinetti, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Magdalene Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergard, Tomas Olsson, Fredrik Piehl, Thomas Frisell

Summary: This study analyzed a Swedish nationwide observational study on RRMS to identify trajectories of processing speed and physical disability after DMT start. The results showed that patients' processing speed remained stable over time, while those with moderate physical disability experienced deterioration in physical function. However, there was a strong association between processing speed and disability.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS)

Juliette Foucher, Ivar Winroth, Aniko Lovik, Stefan Sennfalt, Joana B. B. Pereira, Fang Fang, Dorothee Lule, Peter M. M. Andersen, Caroline Ingre

Summary: This study validates the validity and reliability of SK-ECAS Version A for detecting cognitive impairment in newly diagnosed ALS patients.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial

Jeremy M. Shefner, Bill Jacobsen, Stuart Kupfer, Fady I. Malik, Lisa Meng, Jenny Wei, Andrew A. Wolff, Stacy A. Rudnicki

Summary: In an ALS clinical trial, the relationship between measurements of strength, function, and quality of life was assessed. The results showed a strong correlation between muscle strength quantified by dynamometry and functional capacity, indicating a direct relationship between muscle strength and specific functions important to ALS patients.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

暂无数据